A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer. READ MORE
A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer.
Factors predicting HER2 discordance between primary tumor and circulating tumor cells may be used as a surrogate for tumor biology and tumor heterogeneity in patients with breast cancer.
Researchers examined whether low levels of pre-existing cytotoxic tumor-infiltrating lymphocytes can predict the response to antibody- and molecule-based drugs in metastatic HER2-positive breast cancer.
Halting adjuvant endocrine therapy for ER-positive breast cancer after 5 years does not reduce the risk of cancer recurrence in the long-term.
Research in Review
An immuno-agent improves PFS and lowers the risk of death for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation.
A low level of stromal cytotoxic T-cell infiltration in breast cancer tumor specimens predicts patients who may benefit most from antibody- vs molecular-based HER2 inhibitors.
A neoadjuvant chemotherapy combination used to treat breast cancer increases the risk of disease metastasis.
In younger women with hormone receptor-positive breast cancer, ovarian function suppression after surgery drives large improvements in breast cancer-free interval when combined with drug therapy.
Genomic analysis revealed differences in the landscape of estrogen receptor-positive cancers when compared with ER+ primary tumors.
Observation for adverse reactions following trastuzumab serves as an unnecessary use of health resources.
Common menopausal symptoms can be used as predictive tools for adherence to the aromatase inhibitor tamoxifen.
Investigators reported results from a clinical trial comparing accelerated partial breast irradiation with whole breast irradiation.